Trial Profile
Assessing Platelet Inhibitory Response to Clopidogrel - Feasibility, Safety and Cost Analysis of a Tailored Platelet Inhibition Strategy for Elective PCI Patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 02 Oct 2012
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel (Primary)
- Indications Cardiovascular disorders; Deep vein thrombosis; Myocardial infarction; Pulmonary embolism; Restenosis; Stent thrombosis; Stroke
- Focus Therapeutic Use
- 03 Sep 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 01 Jun 2011 New trial record